Halozyme Therapeutics (HALO) return on equity (ROE)

Return on equity · fiscal 2025
649.2%

Halozyme Therapeutics (HALO) earned a return on equity of 649.2% in fiscal 2025 (the year ended December 31, 2025). That is 527.1 percentage points higher than the 122.1% of fiscal 2024. Figures as of 18 Nov 2026, 00:02 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
649.2%
Change on fiscal 2024
+527.1 pts
Highest on record
649.2%fiscal 2025
Lowest on record
-845.4%fiscal 2009
Fiscal years on record
152009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Halozyme Therapeutics return on equity (ROE), in more detail

Across the 15 fiscal years on record (2009–2025), the highest was 649.2% in fiscal 2025 and the lowest -845.4% in fiscal 2009. The fiscal 2025 figure is higher than in every one of the 14 earlier fiscal years on record, whose median is -53.6%.

History · 15 fiscal years

Return on equity by fiscal year

Halozyme Therapeutics return on equity (ROE), year by year

Halozyme Therapeutics (HALO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025649.2% 527.1 pts up
2024122.1% 213.9 pts down
2023336.0% 217.0 pts up
2022119.0% 85.4 pts down
2021204.5% 119.0 pts up
202085.5% 164.2 pts up
2019-78.7% 46.4 pts down
2018-32.3% 62.5 pts down
201730.2%—
2015-75.0% 90.4 pts up
2014-165.3%—
2012-109.6% 71.7 pts up
2011-181.4% 80.3 pts up
2010-261.6% 583.8 pts up
2009-845.4%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Halozyme Therapeutics and comparable companies
CompanyReturn on equityFiscal year
Fresenius Medical Care FMS7.4%2025
Kymera Therapeutics KYMR-19.7%2025
DaVita DVA773.1%2024
Halozyme Therapeutics HALO649.2%2025
Universal Health Services UHS20.5%2025
Repligen RGEN2.3%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics return on equity (ROE): questions and answers

What is Halozyme Therapeutics's return on equity?

Halozyme Therapeutics (HALO) earned a return on equity of 649.2% in fiscal 2025 (the year ended December 31, 2025). That is 527.1 percentage points higher than the 122.1% of fiscal 2024.

Is Halozyme Therapeutics's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in every one of the 14 earlier fiscal years on record, whose median is -53.6%.

What are the highest and lowest return on equity figures on record for Halozyme Therapeutics?

Across the 15 fiscal years on record (2009–2025), the highest was 649.2% in fiscal 2025 and the lowest -845.4% in fiscal 2009.

How is Halozyme Therapeutics's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.